Liquid Urine Control Level 3 For Professional Use in the quality control monitoring of In-Vitro Diagnostic Urinary Clinical Assays on a range of clinical chemistry systems.
Publicado el 7 de junio de 2017 · Inicio del retiro: 27 de abril de 2017
Resumen
FDA registra el retiro Z-2167-2017 de dispositivos médicos de Clase III, publicado el 7 de junio de 2017 e iniciado el 27 de abril de 2017. Empresa responsable: Randox Laboratories; Estado: Finalizado; Cantidad reportada: 198 kits; Lote: Catalogue number UC5075 Batch number 907UC. La Clase III indica que no es probable que el producto cause consecuencias adversas para la salud.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
According to Randox Laboratories an investigation indicates a labelling error for 2 of the test methods listed for quantification of Total Protein (urine). The values for the mean of all instruments are incorrect by a factor of 10. Instrument specific values are correct. This does not affect the performance or stability claims of the product. As control results will be outside of the quoted range this may result in a delay in reporting the sample test results. However as the correct instrument specific means are also included in the value sheet this delay is unlikely. Customers have been referred to their Medical Director for further advice
Qué hacer
Voluntary: Firm initiated · E-Mail
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Randox Laboratories
- Distribuidor
- Worldwide Distribution - US Distribution to Puerto Rico and to the countries of : Canada Kuwait Chile Poland China Romania France Saudi Arabia Guatemala Slovenia Iran UAE India UK Italy Uruguay Iraq
- Lote
- Catalogue number UC5075 Batch number 907UC
- Clasificación de riesgo
- Class III
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDARX Imola (RX4900) For Professional Use for the quantitative in vitro determination of various clinical13 de junio de 2018
- FDAPausch Uroview FD fluoroscopic X-ray system UDI number (01)04260491620040 Primarily for urological7 de junio de 2017
- FDAAIA-PACK TPOAb CONTROL SET7 de junio de 2017
- FDAThe Green Herb 100% Natural AL-ER-G, 60 and 150 Capsules, Dietary supplement, This item is packed in a white7 de junio de 2017
- FDA1000 ml Canister (with Gel) for InfoV.A.C. and V.A.C.ULTA Therapy Systems (Part Number M8275093/5). The7 de junio de 2017
- FDAQueso Hondureno, Queso Duro Blando - Honduran Cheese, Dry Hard Cheese; 1 lb 454 g7 de junio de 2017
Preguntas sobre este retiro
¿Liquid Urine Control Level 3 For Professional Use in the quality control monitoring of In-Vitro Diagnostic Urinary Clinical Assays on a range of clinical chemistry systems. fue retirado del mercado?
Sí. FDA publicó el retiro Z-2167-2017 el 7 de junio de 2017. Peligro reportado: According to Randox Laboratories an investigation indicates a labelling error for 2 of the test methods listed for quantification of Total Protein (urine). The values for the mean of all instruments are incorrect by a factor of 10. Instrument specific values are correct. This does not affect the performance or stability claims of the product. As control results will be outside of the quoted range this may result in a delay in reporting the sample test results. However as the correct instrument specific means are also included in the value sheet this delay is unlikely. Customers have been referred to their Medical Director for further advice
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · E-Mail